Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old

• मुख्य लेखकों: Desirée Van Oorschot (लेखक), Anastassia Anastassopoulou (लेखक), Barbara Poulsen Nautrup (लेखक), Lijoy Varghese (लेखक), Alfred von Krempelhuber (लेखक), Mohamed Neine (लेखक), Stéphane Lorenc (लेखक), Desmond Curran (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Taylor & Francis Group, 2019-01-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Each year, around 300,000 Herpes Zoster (HZ) cases are observed in the German population, resulting in costs over €182 million to society. The objective of this study was to estimate the potential public health and economic impact of the new Adjuvanted Recombinant Zoster Vaccine (RZV, Shingrix) in t...